Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

被引：168

作者：

Catala, A. ^{[1
]}

Munoz-Santos, C. ^{[2
]}

Galvan-Casas, C. ^{[3
]}

Roncero Riesco, M. ^{[4
]}

Revilla Nebreda, D. ^{[4
]}

Sola-Truyols, A. ^{[5
]}

Giavedoni, P. ^{[1
]}

Llamas-Velasco, M. ^{[6
]}

Gonzalez-Cruz, C. ^{[7
]}

Cubiro, X. ^{[8
]}

Ruiz-Villaverde, R. ^{[9
]}

Gomez-Armayones, S. ^{[1
]}

Gil Mateo, M. P. ^{[10
]}

Pesque, D. ^{[11
]}

Marcantonio, O. ^{[11
]}

Fernandez-Nieto, D. ^{[12
]}

Romani, J. ^{[13
]}

Iglesias Pena, N. ^{[14
]}

Carnero Gonzalez, L. ^{[15
]}

Tercedor-Sanchez, J. ^{[16
]}

Carretero, G. ^{[17
]}

Masat-Tico, T. ^{[18
]}

Rodriguez-Jimenez, P. ^{[6
]}

Gimenez-Arnau, A. M. ^{[11
]}

Utrera-Busquets, M. ^{[19
]}

Vargas Laguna, E. ^{[20
]}

Angulo Menendez, A. G. ^{[21
]}

San Juan Lasser, E.

Iglesias-Sancho, M. ^{[22
]}

Alonso Naranjo, L. ^{[23
]}

Hiltun, I ^{[24
]}

Cutillas Marco, E. ^{[25
]}

Polimon Olabarrieta, I ^{[3
]}

Marinero Escobedo, S. ^{[3
]}

Garcia-Navarro, X. ^{[26
]}

Calderon Gutierrez, M. J.

Baeza-Hernandez, G. ^{[27
]}

Bou Camps, L.

Toledo-Pastrana, T. ^{[28
]}

Guilabert, A. ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Serv Dermatol, Barcelona, Spain

[2] Hosp Gen Granollers, Serv Dermatol, Barcelona, Spain

[3] Hosp Univ Mostoles, Serv Dermatol, Madrid, Spain

[4] Complejo Asistencial Univ Salamanca, Serv Dermatol, Salamanca, Spain

[5] Hosp Univ Son Llatzer, Serv Dermatol, Mallorca, Spain

[6] Hosp Univ La Princesa, Serv Dermatol, Madrid, Spain

[7] Hosp Univ Vall DHebron, Serv Dermatol, Barcelona, Spain

[8] Hosp Santa Creu & Sant Pau, Serv Dermatol, Barcelona, Spain

[9] Hosp Univ San Cecilio, Serv Dermatol, Granada, Spain

[10] Hosp Gen La Palma, Serv Dermatol, Santa Cruz De Tenerife, Spain

[11] Univ Autonoma Barcelona, IMIM, Hosp Mar, Serv Dermatol, Barcelona, Spain

[12] Hosp Raman & Cajal, Serv Dermatol, Madrid, Spain

[13] Parc Tauli Hosp Univ, Serv Dermatol, Barcelona, Spain

[14] Hosp Univ Lucus Augusti, Serv Dermatol, Lugo, Spain

[15] Hosp Univ Araba, Serv Dermatol, Vitoria, Spain

[16] Hosp Virgen de las Nieves, Serv Dermatol, Granada, Spain

[17] Hosp Univ Gran Canaria Doctor Negrin, Serv Dermatol, Las Palmas Gran Canaria, Spain

[18] Inst Catala Salut, CAP Cardedeu, Barcelona, Spain

[19] Hosp Comarcal Infanta Elena, Serv Dermatol, Huelva, Spain

[20] Hosp Univ Severo Ochoa, Serv Dermatol, Madrid, Spain

[21] Serv Med Penedes Vilanova & Geltru, Serv Dermatol, Barcelona, Spain

[22] Hosp Univ Sagrat Cor, Serv Dermatol, Madrid, Spain

[23] Hosp Univ Toledo, Serv Dermatol, Toledo, Spain

[24] Complejo Hosp Navarra, Serv Dermatol, Navarra, Spain

[25] Hosp Gen Univ Reina Sofia, Serv Dermatol, Murcia, Spain

[26] Consorci Sanitari Alt Penedes Garraf, Serv Dermatol, Barcelona, Spain

[27] Hosp Univ Fuenlabrada, Serv Dermatol, Madrid, Spain

[28] Hosp Quironsalud Infanta Luisa, Seville, Spain

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 01期

关键词：

COVID-19; VACCINATION;

D O I：

10.1111/bjd.20639

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized. Objective To describe and classify cutaneous reactions after SARS-CoV-2 vaccination. Methods A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. Results From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40 center dot 2%), mRNA-1273 (Moderna; 36 center dot 3%) and AZD1222 (AstraZeneca; 23 center dot 5%) vaccines. Mean patient age was 50 center dot 7 years and 80 center dot 2% were female. Cutaneous reactions were classified as injection site ('COVID arm', 32 center dot 1%), urticaria (14 center dot 6%), morbilliform (8 center dot 9%), papulovesicular (6 center dot 4%), pityriasis rosea-like (4 center dot 9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13 center dot 8% of reactions. The COVID arm was almost exclusive to women (95 center dot 4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61 center dot 9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17 center dot 2%) and urticaria (AZD1222, AstraZeneca, 21 center dot 1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90 center dot 5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. Conclusions Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.

引用

页码：142 / 152

页数：11

共 50 条

[21] Musculoskeletal pain during and after SARS-CoV-2 infection and healthcare utilization: a cross-sectional study
Abelardo de Oliveira Soares Junior
Max dos Santos Afonso
Yohana Pereira Vieira
Juliana Quadros Santos Rocha
Samuel Dumith
Rosália Garcia Neves
Carine Nascimento da Silva
Suele Manjourany Silva Duro
Mirelle de Oliveira Saes
BMC Musculoskeletal Disorders, 24
[22] Musculoskeletal pain during and after SARS-CoV-2 infection and healthcare utilization: a cross-sectional study
Soares Junior, Abelardo de Oliveira
Afonso, Max dos Santos
Vieira, Yohana Pereira
Rocha, Juliana Quadros Santos
Dumith, Samuel
Neves, Rosalia Garcia
da Silva, Carine Nascimento
Duro, Suele Manjourany Silva
Saes, Mirelle de Oliveira
BMC MUSCULOSKELETAL DISORDERS, 2023, 24 (01)
[23] SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave
Moyano, Luz M.
Toledo, Angie K.
Chirinos, Jenny
Vilchez Barreto, Percy Mc Quen
Cavalcanti, Sofia
Gamboa, Ricardo
Ypanaque, Jhon
Meza, Mauro
Noriega, Sheilla
Herrera, Victor
Bazan, Edgar
Requena, Alexandra
Silva, Henry
Burgos, Harold
Leon-Jimenez, Franco
PLOS NEGLECTED TROPICAL DISEASES, 2023, 17 (06):
[24] SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study
Alexandra R Röthlin Eriksen
Kamille Fogh
Rasmus B. Hasselbalch
Henning Bundgaard
Susanne D. Nielsen
Charlotte S. Jørgensen
Bibi F. S. S. Scharff
Christian Erikstrup
Susanne G. Sækmose
Dorte K. Holm
Bitten Aagaard
Jonas H. Kristensen
Cecilie A. Bødker
Jakob B. Norsk
Pernille B. Nielsen
Lars Østergaard
Svend Ellermann-Eriksen
Berit Andersen
Henrik Nielsen
Isik S. Johansen
Lothar Wiese
Lone Simonsen
Thea K.Fischer
Fredrik Folke
Freddy Lippert
Sisse R. Ostrowski
Steen Ethelberg
Anders Koch
Anne-Marie Vangsted
Tyra Krause
Anders Fomsgaard
Claus Nielsen
Henrik Ullum
Robert Skov
Kasper Iversen
BMC Public Health, 22
[25] SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study
Eriksen, Alexandra R. Rothlin
Fogh, Kamille
Hasselbalch, Rasmus B.
Bundgaard, Henning
Nielsen, Susanne D.
Jorgensen, Charlotte S.
Scharff, Bibi F. S. S.
Erikstrup, Christian
Saekmose, Susanne G.
Holm, Dorte K.
Aagaard, Bitten
Kristensen, Jonas H.
Bodker, Cecilie A.
Norsk, Jakob B.
Nielsen, Pernille B.
ostergaard, Lars
Ellermann-Eriksen, Svend
Andersen, Berit
Nielsen, Henrik
Johansen, Isik S.
Wiese, Lothar
Simonsen, Lone
Fischer, Thea K.
Folke, Fredrik
Lippert, Freddy
Ostrowski, Sisse R.
Ethelberg, Steen
Koch, Anders
Vangsted, Anne-Marie
Krause, Tyra
Fomsgaard, Anders
Nielsen, Claus
Ullum, Henrik
Skov, Robert
Iversen, Kasper
BMC PUBLIC HEALTH, 2022, 22 (01)
[26] Adverse cutaneous reactions after mRNA SARS-CoV-2 vaccination in 3 patients: a spectrum of severity
Edgerley, Sarah
Jeimy, Samira
Zhu, Rongbo
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (23) : E807 - E811
[27] Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland
Szmyd, Bartosz
Karuga, Filip Franciszek
Bartoszek, Adrian
Staniecka, Katarzyna
Siwecka, Natalia
Bartoszek, Agnieszka
Blaszczyk, Maciej
Radek, Maciej
VACCINES, 2021, 9 (03) : 1 - 14
[28] Global caregiver concerns of SARS-CoV-2 vaccination in children with cancer: a cross-sectional mixed-methods study
Gumy, Julia M.
Silverstein, Allison
Kaye, Erica C.
Caniza, Miguela A.
Homsi, Maysam R.
Pritchard-Jones, Kathy
Bate, Jessica M.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2023, 40 (04) : 341 - 351
[29] Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India
Selvaraj, Preethi
Muthu, Sathish
Jeyaraman, Naveen
Prajwal, Gollahalli Shivashankar
Jeyaraman, Madhan
CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2022, 14
[30] Perceptions of, and Obstacles to, SARS-CoV-2 Vaccination Among Adults in Lebanon: Cross-sectional Online Survey
Abou-Arraj, Nadeem Elias
Maddah, Diana
Buhamdan, Vanessa
Abbas, Roua
Jawad, Nadine Kamel
Karaki, Fatima
Alami, Nael H.
Geldsetzer, Pascal
JMIR FORMATIVE RESEARCH, 2022, 6

← 1 2 3 4 5 →